July 9, 2024 - NxGen MDx, a leading molecular genetic and pathogen testing laboratory, is proud to introduce its innovative Early Advantage Panel (EAP) and Super Panel. These cutting-edge genetic carrier screens are designed to provide equitable screening options, ensuring comprehensive and accurate results for everyone, regardless of ethnic background. NxGen MDx’s broad Pan-Ethnic panel design philosophy is included in both the Early Advantage Panel and Super Panel. These panels are meticulously developed to offer greater detection and prevention of genetic disorders that contribute to infant mortality rates worldwide.
"Our commitment to inclusivity and precision in genetic testing is unwavering," said Scott Pritchard, Director of Laboratory Operations. "By offering tests that are truly ethnicity-agnostic, we ensure that every individual, regardless of their ethnic background, has access to accurate and reliable genetic information." NxGen MDx’s approach is crucial in identifying genetic conditions early, providing families and healthcare providers with critical information to make informed decisions about health and treatment options.
The Early Advantage Panel (EAP) and Super Panel are both powerful tools that give patients more pregnancy and birthing options, shorten the diagnostic odyssey, and help them prepare for any necessary treatments right after birth. NxGen’s carrier screening offerings are a perfect complement to any patient’s reproductive health plan. For more information about NxGen MDx and our groundbreaking genetic testing solutions, please visit nxgenmdx.com.
Since our founding in 2012, NxGen MDx has continually updated our technologies to keep pace with advances in genetic research and screening techniques. Our screens rely on next-generation sequencing that delivers over 99% accuracy clinical detection rates for most conditions. This powerful technique looks at entire coding regions of genes rather than the abbreviated sequencing or genotyping techniques used by other genetic screening companies. And because we detect genetic pathogenic variants that can be missed by abbreviated screening technologies, you can count on NxGen MDx screening results to give a highly accurate, comprehensive assessment of risk and, ultimately, better outcomes for all.